Treatment Of Acute Deep Vein Thrombosis With Intraclot

本研究的目的是评价重组组织型纤溶酶原激活剂(RtPA)治疗急性深静脉血栓形成的疗效。这项研究旨在评估这种形式的治疗在恢复下肢静脉功能方面的有效性、安全性和成本。已有8名患者接受了治疗。除1例患者外，其余患者均有明显改善。只有两名患者在治疗过程中有证据表明有小的肺血栓，这是在所有接受该方案的患者中进行的肺扫描中检测到的。这些患者都没有临床症状。一名患者发生了无生命危险的二头肌血肿，可能是在rtPA治疗期间自动血压监测引起的。没有其他并发症发生。初步结果已在JAMA的病例报告中提交，并在提交给《美国医学杂志》的一篇文章中发表。

The objective of the study is to evaluate recombinant tissue plasminogen activator (rtPA) for treatment of acute deep vein thrombosis of the lower extremity. The study is designed to evaluate efficacy, safety, and cost of this form of treatment for restoration of venous function in the lower extremity. Eight patients have been treated. All except one patient had significant improvement. Only two patients have had evidence of small pulmonary emboli during treatment, detected on ventilation perfusion lung scans that are obtained in all patients accepted into the protocol. None of these patients were clinically symptomatic. One patient developed a non-life-threatening biceps hematoma probably induced by automatic blood pressure monitoring during the rtPA treatment. No other complications have occurred. Preliminary results have been submitted for publication in a case report for JAMA, and in an article submitted to the American Journal of Medicine.